Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Pulmonares/cirurgia , Pneumonectomia , Adulto , Ensaios Clínicos como Assunto , Ciclofosfamida/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Humanos , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Cuidados Pós-Operatórios , Distribuição AleatóriaRESUMO
The results of a cooperative randomized study performed in Poland, Bulgaria, Czechoslovakia, Hungary, and the Soviet Union on the treatment of lung cancer patients are presented. Three hundred and sixty patients were treated only surgically, 360 patients received combined therapy. Adjuvant chemotherapy was performed using 3 preparations (cyclophosphane, methotrexate, 5-fluorouracil) within 2-3 weeks after operation (first course) followed by another 3 courses at intervals of 8-9 weeks. The combined therapy increased the 5-year survival rate of patients with Stage III squamous cell carcinoma with thoracic lymph node metastases. Better results were achieved when 3-4 courses of adjuvant chemotherapy were performed. In patients with Stage I-II squamous cell carcinoma of the lung without regional lymph node metastases the used regimen of combined therapy had no significant effect.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/cirurgia , Terapia Combinada , Ciclofosfamida/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Humanos , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/cirurgia , Metástase Linfática , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Distribuição Aleatória , Estatística como AssuntoRESUMO
The results of a cooperative study on combined treatment and preoperative radiotherapy in 478 lung cancer patients were analyzed. Intensive fractionated radiotherapy was given at doses of 4 Gy for 5 days, the total dosage thus attaining 20 Gy. 218 patients received combined treatment, 260 patients were treated only surgically. A comparison of the 5-year survival rates of Stage I and II patients did not show any advantage in favor of the used therapeutic modality. The combined treatment with preoperative radiotherapy, however, improved the survival rates of Stage III patients with non-small cell lung cancer. The 3-year rate in these patients was 49.4% and the 5-year rate was 29.2%, while those found in the patients treated only surgically were 28.1% and 15.8%, respectively. In all patients with regional metastases the effectiveness of the treatment was higher when the combined method was employed.
